Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 billion in development, regulatory, and commercial milestones, as well as tiered royalties Novartis to be responsible for worldwide clinical development and commercialization of ARV-766 Partnership expected to accelerate and broaden the... Read More